A US commission has urged lawmakers to move quickly to prevent what it calls an “overdependence” on China in the biopharma sector, according to BioPharma Dive. The panel warns that such reliance could make American patients vulnerable if China decides to disrupt supply chains.
This warning signals a strategic risk for pharma and biotech leaders, who may need to review their own supply chain dependencies. The commission’s concerns suggest that sourcing and resilience planning should be a priority for companies with global operations.